Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.
about
Patients' expectations about effects of chemotherapy for advanced cancerOutcomes and quality of life following breast cancer treatment in older women: when, why, how much, and what do women want?Capturing users' experiences of participating in cancer trials.Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients.Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.Developing safety criteria for introducing new agents into neoadjuvant trialsBreast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.Treatment priorities in oncology: do we want to live longer or better?Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls.Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferencesCollaborative Initiatives in the Care of Early Stage Breast Cancer: Reduction in Variation of Breast-Conserving Therapy.Patient preferences and treatment adherence among women diagnosed with metastatic breast cancerExploring health preferences in sociodemographic and health related groups through the paired comparison of the items of the Nottingham health profile.Quality of life outcomes in patients with breast cancerEndpoints in advanced breast cancer: methodological aspects & clinical implications.The quality of medical care at the end-of-life in the USA: existing barriers and examples of process and outcome measures.Eliciting women's preferences in health care: a review of the literature.Letrozole in advanced breast cancer: the PO25 trial.Osteoporosis medication profile preference: results from the PREFER-US studySubjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials.Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferencesPatients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice.'Being there' for women with metastatic breast cancer: a pan-European patient survey.Methodologic evaluation of adaptive conjoint analysis to assess patient preferences: an application in oncology.Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message?Discerning the clinical relevance of biomarkers in early stage breast cancer.Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions.Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.Age and adjuvant chemotherapy use after surgery for stage III colon cancer.Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients.Perception of chemotherapy side effects cancer versus noncancer patients.An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment.
P2860
Q24597282-F7833F72-A643-4558-9AB6-719742C7078DQ24804538-548FADB1-194C-47ED-B195-3EED6244A33EQ31111327-E9D43253-4D8E-47DB-B0B9-C5F6B31DF478Q33806752-FDF40828-CADE-44AD-A716-CD1E8C1E89BCQ33837105-C1BAA58D-7CEA-4DF3-897C-809F973E00AAQ33865329-6CF3BDC3-6A07-41EA-8D6B-05E3DA6925A7Q33895825-BAD490FC-A559-4DA1-8EC4-AC3C67C4F336Q33990818-33C2F54C-3BFA-4A0B-93E3-ACDB272920EFQ34031335-F36F59A3-CF97-4F29-9093-5B36BC480A08Q34048798-10C0AC7C-7539-4328-8729-64277611910EQ34067540-CB72D748-EE8F-4EA3-8437-39FD169B20DDQ34248661-3FBFFAA2-35FE-425F-B5A5-BDD21124F6D8Q34720400-0F6BA337-4753-416C-877B-C0A20EAB47D0Q35402477-BBEC9117-4C8D-4E5C-927C-03BF1E17BCA8Q35569374-9F1D9F8D-FE14-49C5-8097-5F00070C1D8DQ35611036-48B396EB-5E41-4AB8-848D-423E7F89639EQ35805736-CDF034EE-67A4-4E82-AF4D-2411838E05D1Q35812283-3EC4CDA1-24BE-4663-9BEE-CE2A5EB50D12Q36026424-C5A11031-92B3-4CA8-81FC-5905AEF25F5CQ36088579-239BF8B8-6F34-4E29-93EA-3A1293A43F5DQ36292207-F774BDEE-E277-4262-B263-5A788F157E32Q36611201-23884AD0-DA25-4FFB-A402-EDA694C9C3F4Q36622427-ED29692A-7705-4ECC-ACA7-6D90385EC886Q36673526-AD212E96-5AC1-4AD3-AD3B-27A67C69B984Q37182271-5492C6C1-CE45-4261-8634-A435281048DAQ37332615-15232E38-C235-4C3D-9CB4-041B95A24D69Q37385471-F88C166F-09F4-4CAF-A42E-E377EBC80999Q38841237-7409812B-4C4F-4576-BD05-0F3D4F16148DQ40865994-A3CC4F6E-7AFE-465C-A0C2-704265870E0BQ43481926-1D29269D-DBB4-42A8-B17C-55E1E14EFBF2Q43534600-5C562BA3-E877-4550-9976-D6A09633ECD0Q51018331-15403DC0-0614-4CEE-8284-23F9E59BADA0Q51102883-9B8A7FA8-2694-47C3-A85A-37E023C99D7BQ52535212-566CA6AE-862B-4948-999F-57EF5D65019DQ55395025-183FE902-9BEB-4415-93C2-6155563A0C17
P2860
Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Patient preferences for treatm ...... ith early-stage breast cancer.
@en
Patient preferences for treatm ...... ith early-stage breast cancer.
@nl
type
label
Patient preferences for treatm ...... ith early-stage breast cancer.
@en
Patient preferences for treatm ...... ith early-stage breast cancer.
@nl
prefLabel
Patient preferences for treatm ...... ith early-stage breast cancer.
@en
Patient preferences for treatm ...... ith early-stage breast cancer.
@nl
P2093
P1476
Patient preferences for treatm ...... ith early-stage breast cancer.
@en
P2093
R P McQuellon
S B Yellen
S L Hoffman
P304
P356
10.1200/JCO.1995.13.4.858
P407
P577
1995-04-01T00:00:00Z